What Happened?
Shares of healthcare tech company Omnicell (NASDAQ:OMCL) fell 17.5% in the afternoon session after the company reported weak first-quarter 2025 results, which featured full-year EPS and EBITDA guidance that fell short of Wall Street's estimates.
On the other hand, Omnicell blew past analysts' EPS and revenue estimates. Still, this was a weaker quarter.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Omnicell? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Omnicell’s shares are quite volatile and have had 16 moves greater than 5% over the last year. But moves this big are rare even for Omnicell and indicate this news significantly impacted the market’s perception of the business.
Omnicell is down 42.3% since the beginning of the year, and at $25.58 per share, it is trading 51.8% below its 52-week high of $53.05 from October 2024. Investors who bought $1,000 worth of Omnicell’s shares 5 years ago would now be looking at an investment worth $352.00.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.